InChI key
DERJYEZSLHIUKF-UHFFFAOYSA-N
InChI
1S/C12H19N3O.ClH/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3;/h4-7,9,13-14H,8H2,1-3H3,(H,15,16);1H
SMILES string
Cl.CNNCc1ccc(cc1)C(=O)NC(C)C
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to tan
solubility
DMSO: ≥18 mg/mL
storage temp.
2-8°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
Application
Procarbazine hydrochloride has been used to study its physicochemical property.
Procarbazine, an antineoplastic alkylating agent, may be used to study its pharmacokinetics, metabolism, safety, efficacy and methods of delivery as an anticancer agent. It may be used to study new combination of anticancer drugs.
Biochem/physiol Actions
Procarbazine hydrochloride is a Antineoplastic alkylating agent
Procarbazine is an antineoplastic alkylating agent widely used in cancer chemotherapy in combination with other compounds. It has multiple mechanisms of action. Procarbazine inhibits protein, RNA and DNA synthesis in addition to being an alkylating agent.
Procarbazine is metabolized to azoprocarbazine either by cytochrome P450 enzyme and monoamine oxidase in an NADPH (nicotinamide adenine diphosphate) dependent or independent manner. It is considered neurotoxic. Procarbazine is used in combination with therapy for treating Hodgkin′s disease.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Carc. 1B - Muta. 2 - Repr. 1A
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Mary R Welch et al.
Neuro-oncology, 14(10), 1304-1311 (2012-09-07)
Up to 20% of all primary CNS lymphoma (PCNLS) patients are aged 80 years or older, yet data are limited on how best to treat this rapidly growing population. Despite demographic pressures and the proven efficacy of methotrexate (MTX)-based regimens
Fourteenth biannual report of the Cochrane Haematological Malignancies Group--focus on autologous stem cell transplantation in hematological malignancies.
Michaela Rancea et al.
Journal of the National Cancer Institute, 104(14), NP-NP (2012-07-25)
Anti-Cancer Drug Design, 143-143 (1994)
Eighth Annual Report on Carcinogens, 181-181 (1999)
eIF2alpha phosphorylation is pathognomonic for immunogenic cell death
Bezu L, et al.
Cell Death and Differentiation, 1-1 (2018)
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持
